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Summary: 
Background: The benefits of monitoring cerebral blood flow (CBF) in stroke patients are 
apparent. New techniques combining near infrared spectroscopy (NIRS) and indocyanine 
green (ICG) dye dilution to estimate cerebral hemodynamics are available. However, with 
transcutaneous NIRS and optodes applied over the skin, the signal is contaminated by 
extracerebral tissues. The objective is to develop a new brain tissue probe for combined 
monitoring of intracranial pressure (ICP), CBF and cerebral blood volume (CBV). 
Methods: Conventional intraparenchymal probes for ICP monitoring are supplied with 
optical fibers. The light is coupled into the brain tissue and collected after absorption and 
scattering with a light detector. Venous injections of 0.2mg/kgbw ICG are performed. The 
mean transit time of ICG (mttICG), CBF and CBV are calculated.  
Results: With a prototype of the probe in a first patient with subarachnoid hemorrhage 6 
pairs of repetitive measurements were performed. Mean values were for mttICG 5.6+0.2 sec, 
CBF 22.3+2.8 ml/100g/min and CBV 2.1+0.3 ml/100g. 
Conclusions: NIR spectroscopy allows the synchronous determination of multiple 
parameters with one single device. By measurements in parallel with the NeMo Probe and 
NIRS optodes placed over the skin, new algorithms can be developed to subtract the 
extracerebral contamination from the NIRS signal. 
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Introduction: 
The benefits of monitoring cerebral blood flow (CBF) in patients with subarachnoid 
hemorrhage, severe hemispheric stroke and head injury are apparent. Numerous techniques 
have been developed to estimate cerebral hemodynamics (1, 5, 10, 11, 14, 19). However, each 
method has its own advantages and drawbacks. To date a suitable method for bedside CBF 
measurement, able to detect smaller areas of ischemia and easy to perform at the bedside is 
still lacking.  
Optical methodologies may be the ideal instrument to monitor disease-related secondary 
brain injuries in instable patients in the environment of intensive care, emergency care and 
surgical units. New techniques combining near infrared spectroscopy (NIRS) and indocyanine 
green (ICG) dye dilution to estimate cerebral hemodynamics are available (3, 7, 8, 13, 15). 
However, transcutaneous NIRS with optodes applied over the skin is controversially 
discussed, because the NIRS signal is contaminated by extracerebral tissues (skin, skull, 
cerebrospinal fluid layer) (4, 6, 17). To obtain measurement values directly from the brain 
tissue a conventional probe for intracranial pressure (ICP) monitoring can be supplied with 
optical fibers for NIRS. For patients with severe brain injuries and stroke, where ICP probes 
are installed anyway because of brain oedema and intracranial hypertension, a new combined 
NIRS ICP probe may offer enhanced modality without an additional surgical intervention. 
The objective is to develop a new intraparenchymal probe for combined monitoring of 
ICP, brain temperature, CBF and cerebral blood volume (CBV) with NIRS and ICG dye 
dilution. 
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Methods: 
The study was approved by the Ethics Committee of the University of Zurich. 
Measurements were performed in a patient with severe subarachnoid hemorrhage Hunt and 
Hess grade 5, Fisher 4 with ruptured aneurysm of the anterior communicating artery. Because 
of occlusive hydrocephalus a ventricular catheter (Bactiseal®, Codman, Johnson & Johnson, 
USA) was inserted to drain cerebrospinal fluid. After coiling the ruptured aneurysm, the 
patient developed brain edema and ICP monitoring with an intraparenchymal probe was 
needed. A prototype of the new NIRS ICP probe (NeMo Probe®, NeMoDevices AG, 
Switzerland) was inserted through a support bolt (Raumedic®, Germany) from a burr hole by 
an experienced neurosurgeon in the ICU (figure 1). The probe was placed into the brain 
tissue, 2cm deep from the dura. The correct positioning of the probe was confirmed with 
computed tomography (CT) (figure 2). 
For NIRS, conventional intraparenchymal probes for ICP monitoring (diameter 6 French) 
were supplied with optical fibers (NeMo Probe®, NeMoDevices, Switzerland). The light is 
coupled out into the brain tissue via a metalized microprism and collected after absorption and 
scattering with a light detector. A thermistor and an ICP sensor (microminiature strain gauge 
pressure sensor) were included at the tip of the probe. Before implantation the ICP sensors 
were extensively tested over 8 days and showed no significant measurable drift. A NIRS 
apparatus, specifically constructed for the measurement mode (NeMo System®, 
NeMoDevices, Zuerich, Switzerland) include the light sources, the hardware for data 
collection and the software to analyze the NIRS data (NeMo View®) (figure 3). Regular 
measurements were performed daily and repeated after 15 mins under stable clinical 
conditions (unchanged ICP, mean arterial pressure, paCO2). Central venous injections of 
0.2mg/kgbw ICG were performed, followed by the injection of 10ml Glucose 5% flush. The 
ICG concentrations were calculated based on the changes in OD. Regional values for the 
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mean transit time of ICG (mttICG), CBF and CBV were calculated according to published 
algorithms (8). 
Statistical analysis: Standard deviation and coefficient of variation were calculated for 
repeated measurements. ICP values were compared using the correlation coefficient and 
paired t-test. 
 
Results: 
In a first patient with subarachnoid hemorrhage, with two prototypes of the new brain 
tissue probe 16 measurements with ICG injections were performed on 4 consecutive days. No 
complications associated with the measurement technique occurred. The user-acceptance by 
neurosurgeons and ICU staff was as high as for conventional brain tissue probes for ICP 
monitoring. Day 3, the first probe had to be changed because of decreased signal to noise 
ratio. Day 5, before an additional measurement could be performed, the probe was pulled out 
by the nurse accidentally. In 12 single, 6 pairs of measurements, data analysis was successful. 
Mean values were for mttICG 5.6 + 0.2 sec, CBF 22.3 + 2.8 ml/100g/min and CBV 2.1 + 0.3 
ml/100g. The coefficients of variation for repetitive measurements were for mttICG 0.046, 
CBV 0.18 and CBF 0.14. 12134 ICP values obtained with the NeMo Probe (ICPNeMo) were 
compared with ICP values measured with a conventional ventricular drainage and an external 
tranducer (ICPVD). The correlation coefficient between ICPNeMo and ICPVD was 0.7219 (95% 
CI 0.7132 to 0.7303; p<0.0001).  
 
Discussion: 
Originally, as scientific prototypes, the optical fibers for combined NIRS and ICP 
monitoring were first integrated into a conventional subdural probe for ICP-monitoring and 
tested in two patients (9). Still, in clinical practice the use of ICP probes constructed as 
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subdural types is not common yet, as intraparenchymal probes are preferred due to their 
higher measuring accuracy and their smaller diameter which makes their application less 
invasive (2, 16). Therefore, the industrialized prototypes are now being produced as probes to 
be inserted directly into the brain tissue. 
Two prototypes of the new intraparenchymal NIRS ICP probe could be tested in a first 
patient and values for mttICG, CBF and CBV could be determined. The measured values 
obtained with the NIRS ICP probe with a mean CBF of 22.3 + 2.8 ml/100g/min and a mean 
CBV of 2.1 + 0.3 ml/100g correspond to normal values obtained with H215O positron 
emission tomography (PET) (22.2 + 4.9 ml/100g/min for CBF and 2.7 + 0.56 ml/100g for 
CBV) or with dynamic susceptibility contrast magnetic resonance imaging (MRI) (23 + 14 
ml/100g/min for CBF and 1.3 + 0.4 ml/100g for CBV) in the white matter (12, 18). To test 
the accuracy of the measurement method, in a very first step its reproducibility was examined 
with repeated measurements under unchanged clinical conditions. The standard deviations 
and coefficients of variation are clinically well acceptable.  
For patients with severe brain injuries and stroke, where ICP probes are anyway installed 
because of brain oedema and intracranial hypertension, the NeMo Probe offers enhanced 
modality modes (ICP, brain temperature, mttICG, CBF, CBV, changes of oxygenated, 
desoxygenated and total hemoglobin concentrations) without an additional surgical 
intervention. The new multimodal monitoring system provides information of cerebral 
hemodynamics, oxygenation and metabolism synchronously within minutes at the bedside 
and may allow optimising and individualising new neuroprotective therapies for every single 
brain injured patient. 
Like other methods applying brain tissue probes, as microdialysis or brain tissue oxygen 
tension pressure (PbtO2) monitoring, the major restriction of the NeMo System applying the 
NIRS ICP probe is that it is a regional measurement method, giving relevant results only if 
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the probe is inserted into the area of interest. Cerebral vasospasm leading to focal ischemic 
events after subarachnoid hemorrhage may occur in different and multiple vascular territories, 
presumably not being observed by the NeMo Probe. Ongoing theoretical examinations 
applying different model simulations will clarify the extent of the measurement volume of the 
NeMo Probe, which depends not only on the distance between the light emitter and detector, 
but on different light scattering properties under specific pathophysiological conditions in the 
brain tissue. 
The advantages of patches with NIRS optodes applied over the skin, is that they are strictly 
non-invasive. Several vascular territories, therefore, can be monitored over both hemispheres 
symmetrically.  Furthermore, measurements with the NeMo Probe and optode patches over 
the skin in parallel, will allow for the development of algorithms to determine and subtract 
extracerebral contamination. In less severely ill patients, not requiring an ICP monitoring 
probe and in patients treated with full anticoagulation (e.g. during cardiopulmonary bypass 
surgery) the non invasive approach with optode patches attached over the skin and optimized 
algorithms may be the first choice. 
In conclusion: The new combined NIRS ICP probe allows the determination of multiple 
parameters synchronously with one single device. By measurements in parallel with the 
NeMo Probe and NIRS optodes placed over the skin, new algorithms will be developed to 
determine  the contribution from extracerebral tissues within the cumulative signal obtained 
by transcranial NIRS.
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Figure legends: 
 
Figure 1: Dark: NeMo Probe inserted through a support bolt from a burr hole; bright: 
ventricular drainage 
 
Figure 2: Computed tomography (CT) scans showing the NeMo Probe and the ventricular 
drainage (coronar section, bone window) 
 
Figure 3: NeMo System including light sources, data collection unit and software for data 
analysis  
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